Filing Flows › Health Care › TherapeuticsMD (TXMD)
TherapeuticsMD (TXMD) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 11, 2026 · TherapeuticsMD (TXMD) Q2 2026 earnings results →
Q2 2026 Revenue down 9% year over year to $869K · 18¢ of every $1 of revenue kept as net profit · operating margin -93.9%
TherapeuticsMD made $869K in Q2 2026 (-9% Y/Y). Operating margin -93.9%, net earnings $155K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $869K in Q2 2026, down 9% year over year and up 20% from the previous quarter.
Operating costs exceeded revenue by $816K, an operating margin of -93.9%. Total costs grew 2% against a revenue fall of 9%. The fastest-growing cost line was Other operating costs (+12%). Net earnings were $155K, down 72% year over year. The effective tax rate was 5.5%. Non-operating items added $1.0M, 598% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $779K (up 104% year over year), 503% of net earnings. Non-cash charges added back $95K of depreciation and amortization and $4K of share-based compensation. Working capital and other items added $525K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 11, 2026 | $869K | -9% | -93.9% | $155K | $779K |
| Q1 2026 | 10-Q | May 12, 2026 | $724K | +84% | -99.9% | $95K | $944K |
| Q4 2025 | 10-K | Mar 30, 2026 | $893K | +34% | -173.8% | −$619K | $375K |
| Q3 2025 | 10-Q | Nov 12, 2025 | $784K | +43% | -109.9% | $152K | $999K |
| Q2 2025 | 10-Q | Aug 12, 2025 | $952K | +307% | -73.0% | $551K | $381K |
| Q1 2025 | 10-Q | May 13, 2025 | $393K | +26% | -221.6% | −$653K | $699K |
| Q4 2024 | 10-K | Mar 27, 2025 | $667K | +33% | -97.8% | $252K | $17K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About TherapeuticsMD
Throughout this Annual Report on Form 10-K (“2025 10-K Report”), the terms “we,” “us,” “our,” “TherapeuticsMD,” “the Company,” or “our company” refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries vitaMedMD, LLC, a Delaware limited liability company (“vitaMed”), and BocaGreenMD, Inc., a Nevada corporation (“BocaGreen”). TherapeuticsMD is a pharmaceutical royalty company that owns or has rights to trademarks, service marks, or trade names that were previously used in connection with the operation of its business, or are now licensed by another party, including TherapeuticsMD®, vitaMedMD®, BocaGreenMD®, BIJUVA®, and IMVEXXY®, which are protected under applicable intellectual property laws and are the property of the Company.
In its own words, from its 10-K, filed Mar 30, 2026.
TherapeuticsMD against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -9% against the peers' median +7%. Operating margin: -93.9% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TXMD TherapeuticsMD | Q2 2026 | $869K | -9% | -93.9% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: TherapeuticsMD 10-Q on SEC EDGAR · CIK 25743 · Pharmaceutical Preparations
13F: who owns TXMD and who is buying
More on TXMD
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results